CADL
NASDAQ · Biotechnology
Candel Therapeutics Inc
$4.97
+0.06 (+1.22%)
Open$4.91
Previous Close$4.91
Day High$5.17
Day Low$4.85
52W High$43.60
52W Low$28.51
Volume—
Avg Volume723.5K
Market Cap320.06M
P/E Ratio32.65
EPS$1.09
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+857.5% upside
Current
$4.97
$4.97
Target
$47.59
$47.59
$33.44
$47.59 avg
$47.92
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 45.25M | 41.90M | 41.45M |
| Net Income | -4,564,062 | -5,052,559 | -4,078,464 |
| Profit Margin | -10.1% | -12.1% | -9.8% |
| EBITDA | -6,328,796 | -6,835,485 | -6,691,447 |
| Free Cash Flow | -4,822,512 | -5,572,664 | -3,889,078 |
| Rev Growth | -8.7% | -6.2% | +3.8% |
| Debt/Equity | 0.84 | 0.77 | 1.12 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |